Comments
Shares of Aurobindo Pharma slumped more than 5 per cent in the morning trade amid reports that the company has received observations from the US health regulator for one of its Hyderabad units.
According to a media report, the US Food and Drug Administration (USFDA) has issued Form 483 with 9 observations to Aurobindo Pharma’s unit 4 in Hyderabad, citing serious deficiencies in maintaining the manufacturing quality standards.
The stock opened on a weak note at Rs 605.40, then fell to an intra-day low of Rs 590, down 5.46 per cent over its previous closing price. Similarly, on the NSE, the stock opened at Rs 603.10, then fell to an intra-day low of Rs 590, down 5.46 per cent over its last close.
The report added that the FDA representatives had inspected the facility between February 12-20, 2018.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.